Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma — Stella

Recruiting

Back to Pancreatic Ductal Adenocarcinoma (mPDAC) trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

University of California, San Diego, La Jolla, California

Key details

Phase

Safety & dosing

Sponsor

University of California, San Diego

Collaborators

Regeneron Pharmaceuticals

Enrollment target

~43 participants

Started

April 2026

Primary completion

July 2028

Age range

18 Years and older

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov